Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shorter radiation shows promise for prostate cancer control

NCT ID NCT07489729

Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two radiation therapy schedules for men with intermediate- or high-risk prostate cancer. One group received fewer, higher-dose radiation sessions (hypofractionated), while the other received standard daily doses. Both groups also received hormone therapy. The goal was to see which approach better controlled cancer and reduced side effects. The study involved 60 men and measured PSA levels, tumor response, and survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Jun 2022

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Biopsy proven prostate adenocarcinoma * Patient has been classified as intermediate or high risk according to the National Comprehensive Cancer Network v2018 . * Clinically localized stage (cT2-T3b N0M0, using the AJCC 8th TNM classification) . * Eastern Cooperative Oncology Group performance status ranged from 0-1 . - Mean age was 65 years (range: 50-80 years). * a prostate-specific antigen test at the time of diagnosis ≥10 ng/ml. * Gleason scores range from 7 to 10. * The patient must not receive any cytotoxic anticancer therapy for prostate cancer prior to randomization. * Adequate hematological, hepatic, renal function tests Exclusion Criteria: * Patients with a history of other malignancies, except: non-melanoma skin cancer. * Patients with any contraindication to pelvic radiotherapy: including, previous pelvic radiotherapy, inflammatory bowel disease or severe bladder irritability. * Patients who had prior surgical treatment for carcinoma of the prostate apart from trans-urethral resection, * Nodal or distant metastasis proven by a computed tomography pelvis or bone scan, * Co-morbidities as Congestive heart failure, recent myocardial infarction.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypofractionated dose are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypofractionated dose Prostate cancer patients

Contacts and locations

Locations

  • Tanta University

    Tanta, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.